Field Scientific Director (MSL), Payer and Evidence
Amylyx Pharmaceuticals
Summary
The Field Scientific Director, Payer & Evidence is a field-based role within Medical Affairs responsible for advancing Amylyx's Market Access, Health Economics & Outcomes Research (HEOR) and Real-World Evidence (RWE) strategies through impactful engagement with payer decision-makers. This role serves as a critical bridge between clinical evidence, value demonstration, and market access, translating complex data into meaningful insights that support patient access and inform strategic decision-making.
Job description
Field Payer Scientific Engagement
- Work with national, regional and local healthcare decision-makers focused on payer initiatives, RWE, HEOR, and removing clinical and economic barriers to patient access for Amylyx.
- Plan and execute territory level engagement strategy for assigned customers, in alignment with Market Access and Medical Affairs Strategy.
- Establish and maintain scientific relationships with payer medical directors, pharmacy directors, formulary committee members, IDNs, ACOs, and other local/regional healthcare decision-makers.
- Deliver scientific presentations to formulary committees and other key healthcare decision-makers (HCDMs), communicating health economic model and supporting clinical data, and serve as the primary field-based point of contact for related questions.
- Maintain a consistent and productive field presence across the geography to customer meetings, regional and national conferences as needed.
Customer Engagement Excellence
- Identify, develop and maintain collaborative relationships with payer decision-makers by understanding payer needs and priorities, developing and executing a territory strategic plan and customizing the engagement strategy to address their unique needs.
- Utilize and effectively present clinical, humanistic and economic evidence as well as the value proposition of our products in a clear and compelling manner to the payer audience.
- Develop and implement the field HEOR/RWE strategy in collaboration with internal and other field-based Medical and Commercial (Market Access, Medical Affairs, Sales) partners to provide exceptional customer experience.
- Serve as a trusted resource, sharing expertise with customers.
Innovative Partnerships
- Collaborate with payer decision-makers within a designated geographic healthcare ecosystem to understand and address their unique informational needs and challenges.
- Explore opportunities for collaboration on value-based care and research initiatives to facilitate mutually beneficial partnerships.
- Gather and communicate field payer insights, evidence gaps, horizon scanning of health care environmental trends to drive actionable recommendations and inform medical and commercial strategy.
- Partner with field Market Access Account team as well as other field-based teams, including RSDs and Sales to ensure alignment, coordination and consistency in messaging in a compliant manner.
- Partner on RWE/HEOR research initiatives and publication.
US Healthcare System and Payer Expertise
- Serve as a knowledgeable resource for payer decision-makers and internal cross-functional teams on relevant disease states, value-based assessments, healthcare and payer policies, and other payer oriented emerging topics.
- Stay abreast of emerging science, environmental market issues, pricing and regulatory actions relevant to regional and national payer decision-makers.
- Provide training and support to internal teams on payer and value-based healthcare concepts.
Requirements
- Advanced degree in Bio sciences required (PharmD, PhD, MD, DNP, DHSc)
- At least 7 years of experience in a scientific or health-related field-based customer facing role in industry
- Payer experience required
- Deep understanding of the US healthcare system and US value-based decision makers in private and public payers, IDNs and other payer-related customers at the regional and national level
- Demonstrated expertise in HEOR, real-world evidence (RWE) and value assessment, including experience with AMCP Dossiers, FDAMA 114, budget impact and economic models
- Knowledgeable with experience in the application of HEOR/RWE research and data analytics to effectively communicate study findings on a range of clinical and HEOR topics
- High level of scientific excellence, including strong communication skills in translating and presenting complex scientific information in a clear and compelling manner
- Exceptional interpersonal skills with a high level of emotional intelligence and the ability to effectively engage with diverse stakeholders
- High level of business acumen, including broad knowledge of the healthcare environment, understanding of biopharmaceutical industry, strong skills in developing, managing, and executing strategic plans
- Proven ability to work effectively with cross-functional internal teams (e.g., Market Access, Clinical, Medical Affairs, Commercial) to foster a highly collaborative team environment
- Keen ability to quickly and consistently build and maintain high levels of trust with internal and external stakeholders
- Highly resourceful, self-motivated and the ability to thrive in an entrepreneurial environment
- Rare disease experience (preferred)
- Field medical affairs experience as medical science liaison (preferred)
- East Coast near a metropolitan airport (preferred)
Benefits
- Performance-based bonuses
- Equity awards
- Comprehensive benefits package
Company overview
Amylyx Pharmaceuticals is a clinical-stage pharmaceutical company based in Cambridge, Massachusetts, founded in 2013 by co-CEOs Josh Cohen and Justin Klee. The company specializes in developing novel therapies for neurodegenerative diseases with high unmet medical needs, with a particular focus on amyotrophic lateral sclerosis (ALS), Wolfram syndrome, and post-bariatric hypoglycemia. Amylyx's lead investigational therapy, AMX0035, received FDA approval for ALS treatment under the brand name RELYVRIO in September 2022. The company employs a rigorous scientific approach to target multiple pathological pathways in neurodegeneration, with additional pipeline candidates including avexitide for metabolic disorders and AMX0114, an antisense oligonucleotide targeting calpain-2 for ALS. With a team of 201-500 employees, Amylyx combines therapeutic development expertise with commercialization capabilities to address some of medicine's most challenging conditions.